CREST: EFS Subgroup Analyses Based on Disease Stage

22 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai, and Karine Tawagi, MD, University of Illinois, detail the event-free survival subgroup analyses based on disease stage from the CREST study, which investigated sasanlimab in combination with BCG in BCG-naive, high-risk NMIBC.

This post hoc analysis adds further support for the potential of sasanlimab in combination with BCG as a practice-changing treatment in patients with aggressive disease.
Categoria
Oncology
Commenta per primo questo video.

Prossimo